News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Daiichi Pharmaceutical Co., Ltd. Names Dr. Jay Feingold Vice President, Medical Affairs Bolsters Company's Expertise in Areas of Oncology and Hematology


2/11/2010 10:50:04 AM

PARSIPPANY, N.J., Feb. 11 /PRNewswire-FirstCall/ -- Daiichi Sankyo, Inc. (DSI) announced today that Jay M. Feingold, M.D., Ph.D., has been appointed Vice President of Medical Affairs. Dr. Feingold will manage strategic direction of the company's Medical Affairs department and oversee more than 90 scientists, researchers and field-based medical teams responsible for collaborating with the company's clinical research arm, commercial organization and partners. Medical Affairs is responsible for providing physicians, key opinion leaders, regulatory agencies and professional organizations with medical and scientific information in the areas of clinical studies, outcomes research and disease management programs, among others. Dr. Feingold's vast experience in oncology and hematology will continue to drive the company's current cardiovascular portfolio and shape its pipeline.

Dr. Feingold also becomes a member of DSI's Executive Committee, which is responsible for guiding the organization's short- and long-term strategic and financial objectives.

Prior to joining DSI, Dr. Feingold worked with Wyeth Pharmaceuticals, where he most recently led Oncology Global Clinical Development. Prior to that, he was multi-therapeutic area head in Global Medical Affairs with responsibility for the hematology, oncology and central nervous system (CNS) franchises.

About Daiichi Sankyo, Inc.

Daiichi Sankyo Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Tokyo-based Daiichi Sankyo Co., Ltd., which is a global pharmaceutical innovator. The headquarters company was established in 2005 from the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research

Daiichi Sankyo, Inc.



Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES